Karvy Stock Broking has recommended market performer rating on Ranbaxy Laboratories with a target of Rs 600, in its September 22, 2010 research report.
“Ranbaxy Labs will have sole exclusive rights in US for selling Aircept's generic version which is used in the treatment for Alzheimer's. We confirmed the same with the management. Ranbaxy has reiterated its stand on the ability to monetize all its FTF (first to file) opportunities. “
For more stock tips and ideas visit STOCKINDIA.SLINKSET.COM NOW.
From: http://www.moneycontrol.com/news/recommendations/ranbaxy-labsmarket-performer-karvy_486402.html
No comments:
Post a Comment